VSTM: verastem.com Net earnings per share for the last 12 months

Symbol and logo of brand Verastem (VSTM)

Verastem, Inc. is a recognized expert in developing inhibitors to combat genetically specific tumor mutations. The company's operations are accompanied by strict compliance with environmental regulations regarding the disposal of laboratory waste. The rolling annual earnings per share demonstrate the potential for fabless scaling via outsourced synthesis, and the -1.84 level reflects the current magnitude of this fundamental momentum.

VSTM (Verastem, Inc.) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/11/2026

Analytical breakdowns for Verastem, Inc.

- share price and expert price forecast:
Stock Quotes Verastem, Inc.|VSTM - Fair Value Consensus
- market capitalization information:
Market Valuation Verastem Oncology|VSTM - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Verastem|VSTM - Book Capitalization|Market Value to Book Value Ratio verastem.com|VSTM - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital Verastem, Inc.|VSTM - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Verastem Inc|VSTM - Company Cumulative Debt|Debt to Book Value Verastem Oncology|VSTM - Amount of Long-Term Liabilities|Company Short-Term Debts Verastem|Quick Ratio verastem.com
- net income and valuation multiples indicators:
VSTM - Company Profit|Future Profit Verastem, Inc.|VSTM - Company Value to Net Income|Projected Price to Earnings Verastem|VSTM - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Verastem Oncology|VSTM - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Verastem|VSTM - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months verastem.com|VSTM - Earnings per share increase in current year|Earnings growth forecast for next year Verastem, Inc.
Basic company analysis:Verastem, Inc. - VSTM
Manufactured products of Verastem Oncology

To filter risks, Verastem, Inc. (VSTM) must evaluate real capital efficiency via net income divided by the total number of shares over the last 12 months. By analyzing the EPS TTM annual metric, an investor can discern the business's ability to generate income against the backdrop of colossal clinical trial expenditures and fierce patent competition within the targeted oncology sector.

Who Verastem, Inc. competes with

GMAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year EXEL (exelixis.com)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Bio) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Enliven Corp|Earnings per share for the last twelve months ORIC Pharmaceuticals (ORIC)|RLAY (relaytx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics, Inc.)|Net earnings per share for the trailing year Tyra Biosciences Inc|Monte Rosa Tx - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Cullinan Corp|IMRX (Immuneering Corporation) - Net earnings per share for the last 12 months|CCCC: Earnings per share for the last four quarters|BDTX (Black Diamond Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Repare Therapeutics, Inc. RPTX|Net earnings per share (EPS TTM) PMVP|karyopharm.com - Earnings per share for the last 12 months|Propanc Biopharma - Net earnings per share for the last 12 months|Earnings per share for the trailing year BGMS|AADI: Net earnings per share for the last 12 months|Aileron Therapeutics - Earnings per share for the last four quarters|BPMC: Net earnings per share (EPS TTM)|GlycoMimetics - Earnings per share for the trailing year|SWTX (SpringWorks Therapeutics) - Net earnings per share (EPS TTM)